NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: September 15, 2005
Last updated: March 25, 2009
Last verified: March 2009
The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.

Condition Intervention Phase
Erosive Esophagitis
Reflux Esophagitis
Gastroesophageal Reflux Disease
Drug: esomeprazole magnesium (oral medication)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Official Title: A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To determine the relationship between 24-hour intragastric pH at Day 5 and healing status of moderate to severe erosive esophagitis, after 4 weeks of treatment with 2 doses of esomeprazole magnesium.

Secondary Outcome Measures:
  • Secondary outcomes and the relationship to pH will also be assessed.

Estimated Enrollment: 120
Study Start Date: June 2004
Study Completion Date: August 2005

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or non-pregnant, non-lactating female patients between the ages of 18 and 75 years
  • Patients must have moderate to severe erosive esophagitis

Exclusion Criteria:

  • Significant gastrointestinal bleeding
  • Severe heart, lung, liver or kidney disease
  • Esophagitis not related to acid reflux
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00206180

  Show 39 Study Locations
Sponsors and Collaborators
Study Director: Nexium Medical Science Director, MD AstraZeneca
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00206180     History of Changes
Other Study ID Numbers: D9612L00062 
Study First Received: September 15, 2005
Last Updated: March 25, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Esophagitis, Peptic
Gastroesophageal Reflux
Deglutition Disorders
Digestive System Diseases
Duodenal Diseases
Esophageal Diseases
Esophageal Motility Disorders
Gastrointestinal Diseases
Intestinal Diseases
Peptic Ulcer
Stomach Diseases
Anti-Ulcer Agents
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Proton Pump Inhibitors processed this record on May 26, 2016